Eupraxia Pharmaceuticals Inc. (TSX:EPRX)
Canada · Delayed Price · Currency is CAD 9.65
+0.28 (2.99%)
Nov 3, 2026, 4:00 PM EST
Eupraxia Pharmaceuticals Market Cap
Eupraxia Pharmaceuticals has a market cap or net worth of CAD 636 million as of November 3, 2026. It is the 15,222nd most valuable company in the world and the 356th biggest in Canada. Its market cap has increased by 57.12% in one year.
Market Cap
636.00M
Enterprise Value
488.45M
Revenue
n/a
Global Rank
Country Rank
#356 Canada
PE Ratio
n/a
ChartMarket Cap Chart
Since March 9, 2021, Eupraxia Pharmaceuticals's market cap has increased from 78.01M to 636.00M, an increase of 715.32%. That is a compound annual growth rate of 44.90%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 3, 2026 | 636.00M | 21.68% |
| Dec 31, 2025 | 522.69M | 225.34% |
| Dec 31, 2024 | 160.66M | 9.74% |
| Dec 29, 2023 | 146.40M | 85.76% |
| Dec 30, 2022 | 78.81M | 125.87% |
| Dec 31, 2021 | 34.89M | -55.27% |
| Mar 9, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Bright Minds Biosciences | 759.53M |
| Satellos Bioscience | 197.74M |
| Eastwood Bio-Medical Canada | 123.99M |
| Helix BioPharma | 75.61M |
| NurExone Biologic | 47.23M |
| Thiogenesis Therapeutics | 44.09M |
| Sharp Therapeutics | 43.26M |
| Microbix Biosystems | 41.09M |